Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7;6(5):e70197.
doi: 10.1002/mco2.70197. eCollection 2025 May.

Effects of Intensive Systolic Blood Pressure Control on Glycometabolic and Cardiovascular Outcomes in Normoglycemic Patients: A Secondary Analysis of a Randomized Trial

Cheng Yang  1 , Wei-Hua Chen  2 , Jie Qian  1 , Rong-Chong Huang  2 , Jian-Jun Li  1
Affiliations

Effects of Intensive Systolic Blood Pressure Control on Glycometabolic and Cardiovascular Outcomes in Normoglycemic Patients: A Secondary Analysis of a Randomized Trial

Cheng Yang et al. MedComm (2020). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Impact of intensive blood pressure control on dysglycemia incidence and subsequent cardiovascular outcomes or all‐cause death. (A) Study population flow diagram. Among 9361 participants from the Systolic Blood Pressure Intervention Trial (SPRINT), we excluded those with baseline dysglycemia (fasting glucose ≥100 mg/dL), diabetes history, use of antidiabetic medications, or missing glucose data at baseline. The final analysis included 5027 normoglycemic individuals randomized to intensive (n = 2522) or standard (n = 2505) blood pressure lowering. Among participants with normoglycemia, intensive blood pressure lowering was associated with a higher risk of incident dysglycemia (HR 1.21, 95% CI 1.10–1.34), but this was offset by the benefits of reduced cardiovascular events and all‐cause mortality (HR 0.79, 95% CI 0.66–0.93). (B) Cumulative incidence of dysglycemia in participants with normoglycemia. (C) Kaplan–Meier curves of cardiovascular outcome or all‐cause death in patients with new‐onset dysglycemia. HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease.
See this image and copyright information in PMC

References

    1. Khunti K., Chudasama Y. V., Gregg E. W., et al., “Diabetes and Multiple Long‐term Conditions: A Review of Our Current Global Health Challenge,” Diabetes Care 46, no. 12 (2023): 2092–2101. - PMC - PubMed
    1. O'Brien M. J., Lee J. Y., Carnethon M. R., et al., “Detecting Dysglycemia Using the 2015 United States Preventive Services Task Force Screening Criteria: A Cohort Analysis of Community Health Center Patients,” PLoS Medicine 13, no. 7 (2016): e1002074. - PMC - PubMed
    1. Lauder L., Mahfoud F., Azizi M., et al., “Hypertension Management in Patients With Cardiovascular Comorbidities,” European Heart Journal 44, no. 23 (2023): 2066–2077. - PubMed
    1. Yang R., Zhu Y., Xu M., Tao Y., Cong W., and Cai J., “Intensive Blood Pressure Lowering and the Risk of New‐Onset Diabetes in Patients with Hypertension: A Post‐Hoc Analysis of the STEP Randomized Trial,” European Journal of Preventive Cardiology 30, no. 10 (2023): 988–995. - PubMed
    1. Roumie C. L., Hung A. M., Russell G. B., et al., “Blood Pressure Control and the Association With Diabetes Mellitus Incidence: Results From SPRINT Randomized Trial,” Hypertension 75, no. 2 (2020): 331–338. - PMC - PubMed

LinkOut - more resources